Log in

NASDAQ:NITENightstar Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$25.41
MA: $25.41
$25.41
52-Week Range N/A
Volume40 shs
Average Volume185,808 shs
Market Capitalization$852.25 million
P/E RatioN/A
Dividend YieldN/A
Beta2.84
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Read More
Nightstar Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.67 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NITE
CUSIPN/A
Phone44-20-7062-2777

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.89 per share

Profitability

Net Income$-36,860,000.00

Miscellaneous

Employees47
Market Cap$852.25 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NITE News and Ratings via Email

Sign-up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter.

Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions

How were Nightstar Therapeutics' earnings last quarter?

Nightstar Therapeutics PLC (NASDAQ:NITE) announced its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.13. View Nightstar Therapeutics' earnings history.

Has Nightstar Therapeutics been receiving favorable news coverage?

Media coverage about NITE stock has trended very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nightstar Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutNightstar Therapeutics.

Who are some of Nightstar Therapeutics' key competitors?

What other stocks do shareholders of Nightstar Therapeutics own?

Who are Nightstar Therapeutics' key executives?

Nightstar Therapeutics' management team includes the following people:
  • Mr. David Fellows, CEO & Director (Age 62)
  • Mr. Senthil Vel Sundaram, Chief Financial Officer (Age 41)
  • Dr. Gregory Scott Robinson, Chief Scientific Officer (Age 60)
  • Brian Luque, Sr. Mang. of Investor Relations
  • Mr. Seokho Bryan Yoon Esq., Gen. Counsel & Sec. (Age 40)

When did Nightstar Therapeutics IPO?

(NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

What is Nightstar Therapeutics' stock symbol?

Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."

How big of a company is Nightstar Therapeutics?

Nightstar Therapeutics has a market capitalization of $0.00. The company earns $-36,860,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Nightstar Therapeutics employs 47 workers across the globe.

What is Nightstar Therapeutics' official website?

The official website for Nightstar Therapeutics is www.nightstartx.com.

How can I contact Nightstar Therapeutics?

Nightstar Therapeutics' mailing address is 10 MIDFORD PLACE 2ND FLOOR, LONDON X0, W1T5BJ. The company can be reached via phone at 44-20-7062-2777 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.